- Home
- WNW vs SILO Comparison
WNW vs SILO Comparison
Compare WNW & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNW
- SILO
- Stock Information
- Founded
- WNW 2015
- SILO 2010
- Country
- WNW China
- SILO United States
- Employees
- WNW N/A
- SILO N/A
- Industry
- WNW Catalog/Specialty Distribution
- SILO Apparel
- Sector
- WNW Consumer Discretionary
- SILO Consumer Discretionary
- Exchange
- WNW Nasdaq
- SILO Nasdaq
- Market Cap
- WNW 5.3M
- SILO 4.5M
- IPO Year
- WNW 2020
- SILO N/A
- Fundamental
- Price
- WNW $1.89
- SILO $0.63
- Analyst Decision
- WNW
- SILO
- Analyst Count
- WNW 0
- SILO 0
- Target Price
- WNW N/A
- SILO N/A
- AVG Volume (30 Days)
- WNW 82.8K
- SILO 2.2M
- Earning Date
- WNW 07-07-2025
- SILO 08-12-2025
- Dividend Yield
- WNW N/A
- SILO N/A
- EPS Growth
- WNW N/A
- SILO N/A
- EPS
- WNW 9.06
- SILO N/A
- Revenue
- WNW $158,485.00
- SILO $72,102.00
- Revenue This Year
- WNW N/A
- SILO $1.86
- Revenue Next Year
- WNW N/A
- SILO N/A
- P/E Ratio
- WNW $0.20
- SILO N/A
- Revenue Growth
- WNW N/A
- SILO N/A
- 52 Week Low
- WNW $0.95
- SILO $0.41
- 52 Week High
- WNW $70.00
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- WNW 54.20
- SILO 50.79
- Support Level
- WNW $1.74
- SILO $0.60
- Resistance Level
- WNW $1.95
- SILO $0.66
- Average True Range (ATR)
- WNW 0.19
- SILO 0.04
- MACD
- WNW 0.03
- SILO 0.01
- Stochastic Oscillator
- WNW 58.21
- SILO 68.79
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.